Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?
Indian Pacing and Electrophysiology Journal · 2026-09 · 26 (5) · 533-538
DOI: 10.1016/j.ipej.2026.10.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Pacing and Electrophysiology Journal, 2026-09. Verfasst von Sarena Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Touro University Nevada College of Osteopathic Medicine, United States. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Transthyretin cardiac amyloidosis (ATTR-CM) is an increasingly recognized condition caused by the misfolding of transthyretin (TTR) protein, leading to amyloid deposits in various tissues and organs. In 2019, tafamidis was the first FDA-approved disease-modifying therapy to address an unmet need for patients with ATTR-CM, stabilizing TTR proteins and preventing dissociation. Tafamidis has been shown to reduce all-cause mortality and slow decline in functional capacity and quality of life and is generally considered a safe treatment because of its minimal major drug interactions. However, tafamidis has several well-recognized limitations, including high cost, reduced effectiveness in advanced disease stages, limited ability to address established amyloid burden, and limited evidence for advanced polyneuropathy. As new therapies and advancements emerge, further research is needed to compare their relative effectiveness. In this review, we explore the development of tafamidis, pivotal clinical trial results, clinical applications, safety considerations, and future therapeutic directions for ATTR-CM.
Autor:innen und Institutionen
- Touro University Nevada College of Osteopathic Medicine, United States.
- California University of Science and Medicine, United States.
- Division of Cardiology, Department of Medicine, University of California San Francisco, United States; Advanced Heart Failure Comprehensive Care Center, UCSF Health, United States. Electronic address: mandar.aras@ucsf.e…
Förderung
- Pfizer
Zitieren
APA
Yang, S., Hyun, J., & Aras, M. A. (2026). Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?. Indian Pacing and Electrophysiology Journal, 26(5), 533-538. https://doi.org/10.1016/j.ipej.2026.10.002
Vancouver
Yang S, Hyun J, Aras MA. Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?. Indian Pacing and Electrophysiology Journal. 2026;26(5):533-538. doi:10.1016/j.ipej.2026.10.002
BibTeX
@article{Yang2026,
author = {Yang, Sarena and Hyun, Justin and Aras, Mandar A},
title = {Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?},
journal = {Indian Pacing and Electrophysiology Journal},
year = {2026},
volume = {26},
number = {5},
pages = {533--538},
doi = {10.1016/j.ipej.2026.10.002}
}
EUVIMED